SF-36 MCS (model 1) | SF-36 MCS (model 2) | SF-36 MCS (model 3) | SF-36 MCS (model 4) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|

B (95% CI) | β | p Value | B (95% CI) | β | p Value | B (95% CI) | β | p Value | B (95% CI) | β | p Value | |

BASFI | −1.181 (−2.042 to −0.319) | −0.208 | 0.007 | −0.844 (−1.707 to 0.020) | −0.149 | 0.056 | ||||||

ASDAS | −0.736 (−2.574 to 1.101) | −0.058 | 0.430 | −1.817 (−3.501 to −0.132) | −0.143 | 0.035 | ||||||

BASDAI | −1.275 (−2.311 to −0.239) | −0.180 | 0.016 | −1.736 (−2.664 to −0.809) | −0.245 | <0.001 | ||||||

Disease duration | 0.497 (−1.097 to 2.091) | 0.045 | 0.540 | 0.336 (−1.230 to 1.902) | 0.031 | 0.673 | 0.873 (−0.721 to 2.467) | 0.079 | 0.281 | 0.492 (−1.076 to 2.060) | 0.045 | 0.537 |

Age | −0.043 (−0.209 to 0.124) | −0.040 | 0.612 | −0.055 (−0.219 to 0.108) | −0.051 | 0.505 | −0.093 (−0.258 to 0.072) | −0.086 | 0.267 | −0.087 (−0.248 to 0.074) | −0.081 | 0.286 |

BMI | −0.373 (−0.746 to 0.000) | −0.140 | 0.050 | −0.376 (−0.743 to −0.009) | −0.141 | 0.045 | −0.491 (−0.860 to −0.123) | −0.184 | 0.009 | −0.451 (−0.813 to −0.090) | −0.169 | 0.015 |

Gender (male) | 0.178 (−3.282 to 3.638) | 0.007 | 0.919 | −0.258 (−3.673 to 3.158) | −0.010 | 0.882 | 0.590 (−2.909 to 4.088) | 0.023 | 0.740 | −0.204 (−3.641 to 3.234) | −0.008 | 0.907 |

R^{2}=0.10 | R^{2}=0.12 | R^{2}=0.07 | R^{2}=0.10 | |||||||||

adjR^{2}=0.07 | adjR^{2}=0.10 | adjR^{2}=0.04 | adjR^{2}=0.08 |

p Values <0.05 are highlighted in bold.

adjR

^{2}, adjusted R^{2}, a better estimate of the population value of R^{2}; ASDAS, Ankylosing Spondylitis Disease Activity Score; B, regression coefficient; β, standardised coefficient; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, Body Mass Index; R^{2}, an estimate of the proportion of variance in the dependent variable accounted for by the regression; SF-36 PCS, SF-36 Physical Component Summary Score; SF-36 MCS, SF-36 Mental Component Summary Score.